Director, The Center for the Treatment of Obesity and Diabetes, Hospital Oswaldo Cruz, Sao Paulo, Brasil
Ricardo V. Cohen, MD
What is your presentation about?
A refocus on the treatment of type 2 diabetes to weight management as the primary goal, achieved through pharmacological and surgical treatment. Obesity should be viewed as the main target to address in the care of T2D, to halt the disease continuum.
What makes this topic important in 2022?
Weight loss is known to reverse the underlying metabolic abnormalities of type 2 diabetes and, as such, improve glucose control; loss of 15% or more of body weight can have a disease-modifying effect in people with type 2 diabetes, an outcome that is not attainable by any other glucose-lowering intervention.
How did you become involved with this area of diabetes research or care?
I led the first group that published on surgical options with the primary intent to put diabetes in remission and decrease/avoid micro and macrovascular complications.
What are you most looking forward to at the 82nd Scientific Sessions?
Discussions on diabetes and kidney disease, diabetes, and obesity in the youth, and the heterogeneity of T2D.